¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ P5Y:c@u2  
3? F*|E_  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© K]{Y >w  
A~_*vcz  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© [=[>1<L>  
 $^F L*w  
1.Co-stimulators (or co-stimulating molecules) YL_M=h>P  
C:+-T+m[  
2.NK-kB rz%8V igb  
038|>l-9[  
3.Immunoglobulin superfamily 6;WfsG5  
 KTr7z^  
4.antigen-presenting cell (APC) N8!V%i?  
cI~uI '  
5.death domain % ~eIx=s  
{O ]^8#v^  
6.CCR and CXCR ' U]\]Wp  
$#VEC0  
7.Lectin (or mitogen) a<c]N:1  
 n7g}u  
8.Clusters of differentiation, CD) pZo:\n5o  
BG>fLp  
9.B7 family Ass :  
u s j:I`>  
10.Cytotoxic T lymphocyte, CTL) GRM:o)4;#  
T_\Nvzb}  
11.IL-15 and IL-15 receptor (IL-15R) N|JM L  
ENZjRf4  
12.MHC restriction uX82q.u_y  
BK$cN>J  
13.Affinity-chromatography f4%Z~3P  
3j St&+  
14.Cyctosprin A, CsA b |SDg%e  
C K#^`w  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) {KQ-QKxxS  
{}.M(nPtv;  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© O0Z !*Hy  
1zNh& "  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 6d7E@}<  
!uZ)0R  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ GZefeBi  
a/wg%cWG_  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ NL^;C 3u  
|WkWZZ^  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© 1tZ7%0R\g]  
XE#a#  
ÃâÒßѧרҵ£º 8}M-b6R V  
/1y\EEc  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ |*fi!nvk@  
.8%&K0  
Ïû»¯ÄÚ¿Æ£º pyw]ydB  
] /"!J6(e  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ Yt!o Hn  
/4I9Elr  
ѪҺ²¡Ñ§×¨Òµ£º # x+7-hi  
T^ )\  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»